Davis Polk is advising Morgan Stanley & Co. LLC as financial adviser to AbbVie Inc. in connection with its approximately $63 billion acquisition of Allergan plc. The transaction is expected to close in early 2020, subject to regulatory and Allergan’s shareholder approvals.

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. Allergan, headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

The Davis Polk corporate team includes partner Lee Hochbaum and associate Arthur M.T. Burke. Partner Andrew Ditchfield is providing litigation advice. All members of the Davis Polk team are based in the New York office.